Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Justin Ferdinandus, Helen Kaul, Alden Moccia, Richard Greil, Mark Hertzberg, Valdete Schaub, Andreas Hüttmann, Felix Keil, Judith Dierlamm, Mathias Hänel, Urban Novak, Julia Meissner, Johannes Hellmuth, Stephan Mathas, Josée Zijlstra, Alexander Fosså, Andreas Viardot, Sonja Martin, Pratyush Giri, Peter Kamper, Daniel Molin, Janina Jablonski, Michael Fuchs, Andreas Rosenwald, Wolfram Klapper, Hans Eich, Christian Baues, Markus Dietlein, Carsten Kobe, Bastian von Tresckow, Peter Borchmann
Institutions: Düsseldorf University Hospital, University Hospital Cologne, Ente Ospedaliero Cantonale, Swiss Group For Clinical Cancer Research, Istituto Oncologico della Svizzera Italiana, Paracelsus Medical University, Arbeitsgemeinschaft medikamentöse Tumortherapie, Prince of Wales Hospital, Australasian Leukaemia and Lymphoma Group, University of Tübingen, Essen University Hospital, Hanusch Hospital, University Medical Center Hamburg-Eppendorf, Klinikum Chemnitz, University Hospital of Bern, Heidelberg University, Ludwig-Maximilians-Universität München, Max Delbrück Center, Humboldt-Universität zu Berlin, Freie Universität Berlin, Charité - Universitätsmedizin Berlin, Cancer Center Amsterdam, Oslo University Hospital, Universität Ulm, University Hospital Ulm, Robert Bosch Hospital, Royal Adelaide Hospital, Aarhus University Hospital, Nordic Lymphoma Group, Uppsala University, Universitätsklinikum Würzburg, Christian-Albrechts-Universität zu Kiel, University Hospital Münster, University Hospitals of the Ruhr-University of Bochum, Ruhr University Bochum, University of Duisburg-Essen
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108678452